Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Leukemia, Myeloid, Acute 175Leukemia 147Myelodysplastic Syndromes 138Precursor Cell Lymphoblastic Leukemia-Lymphoma 112Lymphoma 99Lymphoma, Non-Hodgkin 86Multiple Myeloma 81Hodgkin Disease 74Leukemia, Lymphocytic, Chronic, B-Cell 69Congenital Abnormalities 62Leukemia, Myeloid, Chronic-Phase 60Myeloproliferative Disorders 57Lymphoma, Large B-Cell, Diffuse 56Neoplasms, Plasma Cell 53Leukemia, Myelomonocytic, Chronic 53Leukemia, Myeloid, Accelerated Phase 52Lymphoma, Follicular 51Lymphoma, Mantle-Cell 47Burkitt Lymphoma 46Leukemia, Myelogenous, Chronic, BCR-ABL Positive 45Lymphoma, B-Cell, Marginal Zone 44Lymphoma, Large-Cell, Immunoblastic 43Blast Crisis 43Anemia, Refractory, with Excess of Blasts 43Primary Myelofibrosis 40Recurrence 36Hematologic Neoplasms 35Graft vs Host Disease 35Myelodysplastic-Myeloproliferative Diseases 34Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 32

Interventions

Decitabine 1Cyclophosphamide 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × TP53 × Busulfan × Clear all
NCT04123392 2019-10-10

Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical University

Phase 2/3 Unknown
196 enrolled
Other neoplasm

TP53

Data powered by HemOnc (CC BY 4.0) Colophon âš¡